Development and pre-clinical testing of a novel hypoxia-activated KDAC inhibitor (2021)
Attributed to:
Chemical bioreductive approaches to targeted radiosensitisation and imaging of tumours
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.26434/chemrxiv.13502706
Publication URI: http://dx.doi.org/10.26434/chemrxiv.13502706
Type: Preprint